Quick Answer
ArriVent BioPharma, Inc. reported Operating Income of -$177.53 million for fiscal year 2025.
ArriVent BioPharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$177.53M | -88.2% |
| 2024 | -$94.31M | -26.4% |
| 2023 | -$74.59M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$38.32M | -58.1% | -14.0% |
| June 30, 2025 | -$33.62M | -30.8% | +49.6% |
| March 31, 2025 | -$66.77M | -223.0% | -175.6% |
| September 30, 2024 | -$24.23M | -45.0% | +5.7% |
| June 30, 2024 | -$25.70M | -13.8% | -24.3% |
| March 31, 2024 | -$20.67M | -69.8% | -23.7% |
| September 30, 2023 | -$16.72M | — | +26.0% |
| June 30, 2023 | -$22.58M | — | -85.5% |
- ArriVent BioPharma, Inc. showed a decrease of -88.2% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, ArriVent BioPharma, Inc.’s operating income has declined by 138.0% (from -$74.59 million to -$177.53 million).
- The most recent figure is from ArriVent BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: